GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Operating Margin %

Tryptamine Therapeutics (ASX:TYP) Operating Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Tryptamine Therapeutics's Operating Income for the six months ended in Dec. 2023 was A$-1.93 Mil. Tryptamine Therapeutics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Tryptamine Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Tryptamine Therapeutics's Operating Margin % or its related term are showing as below:

ASX:TYP' s Operating Margin % Range Over the Past 10 Years
Min: -14113   Med: -7831.3   Max: -1549.6
Current: -1978.82


ASX:TYP's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -158.97 vs ASX:TYP: -1978.82

Tryptamine Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Tryptamine Therapeutics's Operating Income for the six months ended in Dec. 2023 was A$-1.93 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was A$-5.05 Mil.

Warning Sign:

Tryptamine Therapeutics Ltd has never been profitable in the past 3 years. It lost money every year.


Tryptamine Therapeutics Operating Margin % Historical Data

The historical data trend for Tryptamine Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Operating Margin % Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Operating Margin %
Get a 7-Day Free Trial - - - -14,113.00 -1,549.60

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - -1,782.37 -1,223.92 -

Competitive Comparison of Tryptamine Therapeutics's Operating Margin %

For the Biotechnology subindustry, Tryptamine Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tryptamine Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's Operating Margin % falls into.



Tryptamine Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Tryptamine Therapeutics's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=-9.592 / 0.619
=-1,549.60 %

Tryptamine Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-1.925 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tryptamine Therapeutics  (ASX:TYP) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Tryptamine Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tryptamine Therapeutics (ASX:TYP) Business Description

Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines